Navigation Links
Target for lung cancer chemoprevention identified

ORLANDO, Fla. Scientists have identified a biomarker for measuring the success of lung cancer chemoprevention, an emerging frontier in the fight against this disease that has long been stymied by a lack of measureable outcomes. These study results were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

Paul Bunn, M.D., executive director of the International Association for the Study of Lung Cancer and the James Dudley endowed professor of lung cancer research at the University of Colorado Cancer Center at the University of Colorado School of Medicine, said measurements of endobronchial dysplasia, abnormal cell development that can lead to lung cancer, could predict how well a chemoprevention agent is working.

Bunn presented updated results of a study that tested the effect of oral iloprost on the improvement on endobronchial dysplasia in 152 former smokers. As smoking cessation messages take hold and quit rates increase, former smokers are still at greater risk for lung cancer than the general population.

"We told people to quit smoking and they did, but half of our lung cancer cases in the United States are coming from people who are former smokers," he said. "We need to work on ways to repair their lungs through chemoprevention."

Bunn analyzed the effect of iloprost among those who had endobronchial dysplasia at enrollment, and found a significant difference in prevalence of endobronchial dysplasia. Moreover, when they analyzed the effect of iloprost on Ki-67, a measure of cell proliferation, the difference was not significant.

This is an important advancement for the chemoprevention field, Bunn said, because it shows that they can test agents, like iloprost, and measure the effect on endobronchial dysplasia as an outcome. Chemoprevention is a goal for cancer researchers, and many of them liken the idea to heart disease prevention with statins, a major public health advance of the past 50 years.

"The challenge is there has been no real equivalent to cholesterol with cancer. This study shows that endobronchial dysplasia could play that role," he said.

This abstract will be presented at an AACR press conference on Saturday, April 2 at 10:00 a.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can dial in using the following information:

  • U.S. & Canada: (888) 647-7462
  • International: (201) 604-0169
  • Access Code: 244078


Contact: Jeremy Moore
American Association for Cancer Research

Related biology news :

1. Short rotation energy crops could help meet UKs renewable energy targets
2. Study identifies promising target for AIDS vaccine
3. HIV protein unveils vaccine target
4. New research tool targets microRNA expression in zebrafish
5. Insight into parasite family planning could help target malaria
6. Method reveals new view of human nerve cells, opening door to potential drug targets
7. Cancer-related pathways reveal potential treatment target for congenital heart disease
8. U of Alberta researcher discovers potential cancer therapy target
9. Research identifies drug target for prion diseases, mad cow
10. Viral evasion gene reveals new targets for eliminating chronic infections
11. A new drug target in atherosclerosis: The anaphylatoxin C5a
Post Your Comments:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: ... Pierre Laurin , President and Chief Executive Officer of ProMetic, ... Jaffray 27 th Annual Healthcare Conference to be held ... st , at 8.50am (ET) and ProMetic,s ... day. The presentation will be available live via a webcast ...
(Date:11/24/2015)... and NEW YORK , November ... irst investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will ... in immuno-oncology and other areas of unmet medical need. The ... in LSP 5, the latest LSP fund. This is the ...
(Date:11/23/2015)... OAKS, Calif., Nov. 23, 2015   Ceres, Inc ... announced today financial results for the fiscal year ended ... business. --> --> ... commercializing forage and feed products with a better balance ... company signed distribution agreements with several leading crop input ...
(Date:11/23/2015)... -- The royalty-free a greement a ... daclatasvir for 112 low- and m iddle-i ... --> The Medicines Patent Pool (MPP) today ... an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting ... the HCV virus.  The royalty-free licence will enable generic manufacture ...
Breaking Biology Technology: